pulmicort and Eye-Diseases

Pharmacotherapeutics has begun to play an increasingly important role in the management of patients with neovascular age-related macular degeneration (AMD). Because micro- and nano-particulates are currently being evaluated as a potential drug-delivery option for AMD patients, the purpose of this analysis was to describe how micro- and nano-particulates have been used experimentally and what their potential clinical applications may be.. Micro- and nano-particulates have been used primarily on a pre-clinical basis as new drug-delivery devices in experimental models of neovascular AMD.. It is likely that micro- and nano-particulates will become an important component of targeted clinical pharmacotherapeutics in patients with neovascular AMD.

Topics: Animals; Anti-Inflammatory Agents; Budesonide; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Eye Diseases; Humans; Macular Degeneration; Microspheres; Nanostructures; Neovascularization, Pathologic

Burdensome symptoms of allergic rhinitis (AR) include nasal and ocular symptoms such as itching, tearing and redness. Intranasal corticosteroids are efficacious in the treatment of nasal symptoms of AR.. It was the aim of this study to determine the efficacy of the intranasal corticosteroid mometasone furoate nasal spray (MFNS) in relieving ocular symptoms associated with seasonal AR (SAR).. Ocular symptom data were analyzed for subjects >or=12 years of age, randomized to MFNS 200 mug q.d. (n = 176) or placebo (n = 177) in a placebo-controlled, double-blind clinical trial. Post hoc efficacy analysis assessed the mean change from baseline in subject-reported total ocular symptom scores (TOSS) averaged over the treatment period.. Mean baseline TOSS was 4.91 for the MFNS group and comparable (5.05) for the placebo group - combined average for individual symptoms such as itching, tearing and redness ranged from 0 (no symptoms) to 9 (all symptoms, severe). Mean change from baseline in TOSS averaged over days 1-15 was -1.42 for the MFNS group and -0.94 for the placebo group (p = 0.02), for an observed treatment difference of 0.49 (statistical data rounded to 2 decimal positions). Improvement in individual symptoms (eye itching, tearing and redness) contributed to this treatment effect; the greatest improvement occurred with tearing, which decreased -0.52 from the baseline score 1.59 in the MFNS group and -0.31 from 1.67 in those receiving placebo (p < 0.01), for an observed treatment difference of 0.21. Treatment with MFNS was safe and well tolerated.. MFNS is effective in reducing ocular symptoms of SAR, in addition to its established efficacy in reducing nasal symptoms of SAR.

Topics: Administration, Intranasal; Adolescent; Adult; Aged; Androstadienes; Anti-Allergic Agents; Budesonide; Child; Double-Blind Method; Eye Diseases; Female; Humans; Male; Middle Aged; Mometasone Furoate; Pregnadienediols; Rhinitis, Allergic, Seasonal